PGEN - Precigen

-

$undefined

N/A

(N/A)

Precigen NASDAQ:PGEN Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The Company's technologies enable to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Location: 20374 Seneca Meadows Parkway, Maryland, 20876, US | Website: precigen.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

218.3M

Cash

19.54M

Avg Qtr Burn

-17.49M

Short % of Float

13.01%

Insider Ownership

10.18%

Institutional Own.

63.83%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PRGN-2009 OTS AdenoVerse™ +/- Pembrolizumab Details
Cancer, Solid tumor/s, Squamous cancers

Phase 2

Update

Phase 2

Initiation

PRGN-2012 AdenoVerse™ Details
Recurrent respiratory papillomatosis, Cancer

Phase 1/2

Update

PRGN-3005 UltraCAR-T® Details
Cancer, Ovarian cancer

Phase 1b

Data readout

PRGN-3006 UltraCAR-T® Details
Cancer, Acute myeloid leukemia

Phase 1b

Data readout

PRGN-3007 UltraCAR-T® Details
Cancer, Blood cancer, Solid tumor/s

Phase 1

Update

AG019 ActoBiotics™ Details
Type 1 diabetes, Diabetes

Failed

Discontinued